Our Products & Pipeline
Products in Europe
Our medicines are for the approved indication for which they are authorised in specific countries or regions. This page uses European product trade names with accompanying generic names. Trade and generic names may differ in other markets.
View our approved products in the following countries.
DenmarkAs an adjunct to a reduced-calorie diet and physical activity, QSYMIA is indicated for weight management in adult patients with an initial Body Mass Index (BMI) of:
- ≥30 kg/m2 (obese), or
- ≥27 kg/m2 (overweight) with weight-related co-morbidities such as hypertension, type 2 diabetes or dyslipidaemia
Marketing Authorization
European regulatory agencies in Sweden, Denmark, Finland, Iceland, Norway, and Poland have accepted the Marketing Authorization Application for QSIVA on a decentralized basis. Under the decentralized MAA procedure, the regulatory authorities in each of these member states can simultaneously provide Marketing Authorization for use of a product within those specific countries.
Warnings and Precautions
QSIVA is contraindicated in pregnancy and in women of childbearing potential who are not using effective methods of contraception; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors; or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in QSIVA.
QSIVA can cause fetal harm. It is recommended that patients who can become pregnant obtain a negative pregnancy test result before starting QSIVA treatment, perform monthly pregnancy testing, and use effective contraception while taking QSIVA. If a patient becomes pregnant while taking QSIVA, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.
The most common adverse reactions in adults are paraesthesia, dizziness, an altered or impaired sense of taste, insomnia, constipation, and dry mouth.
LINKS AND RESOURCES
FinlandAs an adjunct to a reduced-calorie diet and physical activity, QSYMIA is indicated for weight management in adult patients with an initial Body Mass Index (BMI) of:
- ≥30 kg/m2 (obese), or
- ≥27 kg/m2 (overweight) with weight-related co-morbidities such as hypertension, type 2 diabetes or dyslipidaemia
Marketing Authorization
European regulatory agencies in Sweden, Denmark, Finland, Iceland, Norway, and Poland have accepted the Marketing Authorization Application for QSIVA on a decentralized basis. Under the decentralized MAA procedure, the regulatory authorities in each of these member states can simultaneously provide Marketing Authorization for use of a product within those specific countries.
Warnings and Precautions
QSIVA is contraindicated in pregnancy and in women of childbearing potential who are not using effective methods of contraception; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors; or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in QSIVA.
QSIVA can cause fetal harm. It is recommended that patients who can become pregnant obtain a negative pregnancy test result before starting QSIVA treatment, perform monthly pregnancy testing, and use effective contraception while taking QSIVA. If a patient becomes pregnant while taking QSIVA, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.
The most common adverse reactions in adults are paraesthesia, dizziness, an altered or impaired sense of taste, insomnia, constipation, and dry mouth.
LINKS AND RESOURCES
IcelandAs an adjunct to a reduced-calorie diet and physical activity, QSYMIA is indicated for weight management in adult patients with an initial Body Mass Index (BMI) of:
- ≥30 kg/m2 (obese), or
- ≥27 kg/m2 (overweight) with weight-related co-morbidities such as hypertension, type 2 diabetes or dyslipidaemia
Marketing Authorization
European regulatory agencies in Sweden, Denmark, Finland, Iceland, Norway, and Poland have accepted the Marketing Authorization Application for QSIVA on a decentralized basis. Under the decentralized MAA procedure, the regulatory authorities in each of these member states can simultaneously provide Marketing Authorization for use of a product within those specific countries.
Warnings and Precautions
QSIVA is contraindicated in pregnancy and in women of childbearing potential who are not using effective methods of contraception; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors; or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in QSIVA.
QSIVA can cause fetal harm. It is recommended that patients who can become pregnant obtain a negative pregnancy test result before starting QSIVA treatment, perform monthly pregnancy testing, and use effective contraception while taking QSIVA. If a patient becomes pregnant while taking QSIVA, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.
The most common adverse reactions in adults are paraesthesia, dizziness, an altered or impaired sense of taste, insomnia, constipation, and dry mouth.
LINKS AND RESOURCES
NorwayAs an adjunct to a reduced-calorie diet and physical activity, QSYMIA is indicated for weight management in adult patients with an initial Body Mass Index (BMI) of:
- ≥30 kg/m2 (obese), or
- ≥27 kg/m2 (overweight) with weight-related co-morbidities such as hypertension, type 2 diabetes or dyslipidaemia
Marketing Authorization
European regulatory agencies in Sweden, Denmark, Finland, Iceland, Norway, and Poland have accepted the Marketing Authorization Application for QSIVA on a decentralized basis. Under the decentralized MAA procedure, the regulatory authorities in each of these member states can simultaneously provide Marketing Authorization for use of a product within those specific countries.
Warnings and Precautions
QSIVA is contraindicated in pregnancy and in women of childbearing potential who are not using effective methods of contraception; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors; or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in QSIVA.
QSIVA can cause fetal harm. It is recommended that patients who can become pregnant obtain a negative pregnancy test result before starting QSIVA treatment, perform monthly pregnancy testing, and use effective contraception while taking QSIVA. If a patient becomes pregnant while taking QSIVA, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.
The most common adverse reactions in adults are paraesthesia, dizziness, an altered or impaired sense of taste, insomnia, constipation, and dry mouth.
LINKS AND RESOURCES
PolandAs an adjunct to a reduced-calorie diet and physical activity, QSYMIA is indicated for weight management in adult patients with an initial Body Mass Index (BMI) of:
- ≥30 kg/m2 (obese), or
- ≥27 kg/m2 (overweight) with weight-related co-morbidities such as hypertension, type 2 diabetes or dyslipidaemia
Marketing Authorization
European regulatory agencies in Sweden, Denmark, Finland, Iceland, Norway, and Poland have accepted the Marketing Authorization Application for QSIVA on a decentralized basis. Under the decentralized MAA procedure, the regulatory authorities in each of these member states can simultaneously provide Marketing Authorization for use of a product within those specific countries.
Warnings and Precautions
QSIVA is contraindicated in pregnancy and in women of childbearing potential who are not using effective methods of contraception; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors; or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in QSIVA.
QSIVA can cause fetal harm. It is recommended that patients who can become pregnant obtain a negative pregnancy test result before starting QSIVA treatment, perform monthly pregnancy testing, and use effective contraception while taking QSIVA. If a patient becomes pregnant while taking QSIVA, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.
The most common adverse reactions in adults are paraesthesia, dizziness, an altered or impaired sense of taste, insomnia, constipation, and dry mouth.
LINKS AND RESOURCES
SwedenAs an adjunct to a reduced-calorie diet and physical activity, QSYMIA is indicated for weight management in adult patients with an initial Body Mass Index (BMI) of:
- ≥30 kg/m2 (obese), or
- ≥27 kg/m2 (overweight) with weight-related co-morbidities such as hypertension, type 2 diabetes or dyslipidaemia
Marketing Authorization
European regulatory agencies in Sweden, Denmark, Finland, Iceland, Norway, and Poland have accepted the Marketing Authorization Application for QSIVA on a decentralized basis. Under the decentralized MAA procedure, the regulatory authorities in each of these member states can simultaneously provide Marketing Authorization for use of a product within those specific countries.
Warnings and Precautions
QSIVA is contraindicated in pregnancy and in women of childbearing potential who are not using effective methods of contraception; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors; or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in QSIVA.
QSIVA can cause fetal harm. It is recommended that patients who can become pregnant obtain a negative pregnancy test result before starting QSIVA treatment, perform monthly pregnancy testing, and use effective contraception while taking QSIVA. If a patient becomes pregnant while taking QSIVA, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.
The most common adverse reactions in adults are paraesthesia, dizziness, an altered or impaired sense of taste, insomnia, constipation, and dry mouth.
LINKS AND RESOURCES
Helpful Links and Resources
LOCATIONS
ABOUT VIVUS